How would you approach adjuvant therapy for a high-risk stage III colon cancer which is MSI-high in a patient >70 years of age?

Benefit of oxaliplatin in patients >70 years of age is not proven and only 5FU/capecitabine in a MSI-H tumor is of questionable efficacy. What would be the best regimen in this scenario?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · Mayo Clinic

Answered on

First, MSI-H stage III colon cancer patients will benefit from oxaliplatin-based adjuvant chemotherapy (Jin et al., PMID 33467526). This is different from stage II MSI-H colon cancer (we do not recommend adjuvant chemotherapy for these patients).

Second, oxaliplatin seemed to be an important compone...

Join for free or sign in to see the full answer